In patients with diabetes mellitus not achieving targets on lifestyle measures, pharmacologic therapy should be considered. Interestingly, in the last years glucose lowering agents have been associated with a number of extra-glycemic effects, including cardiovascular benefits, nephroprotection, and weight loss. Despite the prevalence of diabetes mellitus and the number of patients prescribed with these drugs, only a limited evidence has been available on the effects of pharmacologic therapy for diabetes mellitus on the endocrine system. The impact of SGLT2 inhibitors on aldosterone and GLP-1 receptor agonists on aldosterone and testosterone has been evaluated, but a high level of evidence is still lacking.
The aim of this Research Topic is to call for studies evaluating the impact on the endocrine system of drugs prescribed for diabetes mellitus, with a special focus on SGLT2 inhibitors and GLP-1 receptor agonists. In this attempt, observational and experimental studies and review articles will be gathered from leading scientists in the field of diabetes mellitus.
Areas to be covered in this Research Topic may include, but are not limited to:
- Studies on the effect of SGLT2 inhibitors or GLP-1 receptor agonists on testosterone and gonadotropins in male patients with diabetes mellitus and hypogonadism
- Studies on the effect of SGLT2 inhibitors or GLP-1 receptor agonists on testosterone gonadotropins in female patients with diabetes mellitus and polycystic ovary syndrome
- Studies on the effect of SGLT2 inhibitors or GLP-1 receptor agonists on renin–angiotensin–aldosterone system in patients with diabetes mellitus and arterial hypertension
- Studies on the effect of SGLT2 inhibitors or GLP-1 receptor agonists on Growth Hormone/IGF axis in patients with diabetes mellitus
In patients with diabetes mellitus not achieving targets on lifestyle measures, pharmacologic therapy should be considered. Interestingly, in the last years glucose lowering agents have been associated with a number of extra-glycemic effects, including cardiovascular benefits, nephroprotection, and weight loss. Despite the prevalence of diabetes mellitus and the number of patients prescribed with these drugs, only a limited evidence has been available on the effects of pharmacologic therapy for diabetes mellitus on the endocrine system. The impact of SGLT2 inhibitors on aldosterone and GLP-1 receptor agonists on aldosterone and testosterone has been evaluated, but a high level of evidence is still lacking.
The aim of this Research Topic is to call for studies evaluating the impact on the endocrine system of drugs prescribed for diabetes mellitus, with a special focus on SGLT2 inhibitors and GLP-1 receptor agonists. In this attempt, observational and experimental studies and review articles will be gathered from leading scientists in the field of diabetes mellitus.
Areas to be covered in this Research Topic may include, but are not limited to:
- Studies on the effect of SGLT2 inhibitors or GLP-1 receptor agonists on testosterone and gonadotropins in male patients with diabetes mellitus and hypogonadism
- Studies on the effect of SGLT2 inhibitors or GLP-1 receptor agonists on testosterone gonadotropins in female patients with diabetes mellitus and polycystic ovary syndrome
- Studies on the effect of SGLT2 inhibitors or GLP-1 receptor agonists on renin–angiotensin–aldosterone system in patients with diabetes mellitus and arterial hypertension
- Studies on the effect of SGLT2 inhibitors or GLP-1 receptor agonists on Growth Hormone/IGF axis in patients with diabetes mellitus
